Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...